Zosano Pharma (DB:0ZP) - Prezzo delle azioni, notizie e analisi

This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

0ZP Panoramica delle azioni

Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics and other bioactive molecules to patients suffering from migraine using its transdermal microneedle system.

Informazioni sull'azienda

0ZP analisi fondamentale
Punteggio fiocco di neve
Valutazione	2/6
Crescita futura	0/6
Prestazioni passate	0/6
Salute finanziaria	4/6
Dividendi	0/6

Premi

Analisi del rischio

Has less than 1 year of cash runway

Does not have a meaningful market cap (€13K)

Earnings have declined by 5% per year over past 5 years

Makes less than USD$1m in revenue ($659K)

+ 2 più rischi

Zosano Pharma Corporation Concorrenti

MagForce

DB:MF6

€366.9k

MagForce

XTRA:MF6

€3.6m

graceNT

DUSE:0GM

€27.0k

Spineway

ENXTPA:ALSPW

€199.9k

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Zosano Pharma
Prezzi storici delle azioni
Prezzo attuale dell'azione	US$0.05
Massimo di 52 settimane	US$27.28
Minimo di 52 settimane	US$0.0005
Beta	2.73
1Variazione di 1 mese	-20.00%
Variazione a 3 mesi	-79.68%
Variazione di 1 anno	-99.76%
3Variazione a 3 anni	-99.92%
Variazione a 5 anni	-99.99%
Variazione dall'IPO	-100.00%

Notizie e aggiornamenti recenti

Recent updates

Rendimenti per gli azionisti

	0ZP	DE Medical Equipment	DE Mercato
7D	0%	3.1%	1.0%
1Y	-99.8%	4.8%	11.2%

Ritorno vs Industria: 0ZP underperformed the German Medical Equipment industry which returned -27.6% over the past year.

Rendimento vs Mercato: 0ZP underperformed the German Market which returned -26.1% over the past year.

Volatilità dei prezzi

Is 0ZP's price volatile compared to industry and market?
0ZP volatility
0ZP Average Weekly Movement	918.7%
Medical Equipment Industry Average Movement	5.0%
Market Average Movement	5.0%
10% most volatile stocks in DE Market	11.6%
10% least volatile stocks in DE Market	2.4%

Prezzo delle azioni stabile: 0ZP's share price has been volatile over the past 3 months.

Volatilità nel tempo: 0ZP's weekly volatility has increased from 567% to 919% over the past year.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
2006	40	Steven Lo	www.zosanopharma.com

Zosano Pharma Corporation Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Zosano Pharma con la sua capitalizzazione di mercato?
0ZP statistiche fondamentali
Capitalizzazione di mercato	€12.75k
Guadagni(TTM)	-€55.20m
Ricavi(TTM)	€659.13k

0.0x

Rapporto P/S

0.0x

Rapporto P/E

0ZP è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
0ZP Conto economico (TTM)
Ricavi	US$659.00k
Costo del fatturato	US$20.85m
Profitto lordo	-US$20.19m
Altre spese	US$35.01m
Guadagni	-US$55.19m

Ultimi guadagni dichiarati

Mar 31, 2022

Prossima data di guadagno

n/a

Utile per azione (EPS)	-11.26
Margine lordo	-3,063.13%
Margine di profitto netto	-8,375.11%
Rapporto debito/patrimonio netto	0%

Come si è comportato 0ZP nel lungo periodo?

Vedi performance storica e confronto

This company is no longer active

0ZP Panoramica delle azioni

Premi

Analisi del rischio

Zosano Pharma Corporation Concorrenti

DB:MF6

€366.9k

XTRA:MF6

€3.6m

DUSE:0GM

€27.0k

ENXTPA:ALSPW

€199.9k

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Emergex USA Corporation completed the acquisition of Substantially all assets of Zosano Pharma Corporation for $1 million.

Emergex USA Corp. agreed to acquire Substantially all assets of Zosano Pharma Corporation (OTCPK:ZSAN.Q) for $1.3 million.

Motion for Case Conversion Filed for Zosano Pharma Corporation

Motion for Asset Sale Filed by Zosano Pharma Corporation

Zosano Pharma Corporation to Delist from Nasdaq

Zosano Pharma Corporation Filed for Bankruptcy

Recent updates

Emergex USA Corporation completed the acquisition of Substantially all assets of Zosano Pharma Corporation for $1 million.

Emergex USA Corp. agreed to acquire Substantially all assets of Zosano Pharma Corporation (OTCPK:ZSAN.Q) for $1.3 million.

Motion for Case Conversion Filed for Zosano Pharma Corporation

Motion for Asset Sale Filed by Zosano Pharma Corporation

Zosano Pharma Corporation to Delist from Nasdaq

Zosano Pharma Corporation Filed for Bankruptcy

First quarter 2022 earnings released: US$7.87 loss per share (vs US$2.73 loss in 1Q 2021)

Joseph “Jay” P. Hagan Resigns as Director of the Board of Directors of Zosano Pharma Corporation

Zosano Pharma Corporation Reports Impairment Charges for the First Quarter Ended March 31, 2022

Steven A. Elms Tenders His Resignation as Director of the Board of Directors of Zosano Pharma Corporation

Zosano Pharma Corporation Receives a Response Letter from the U.S. Food and Drug Administration with Regard to the Company’s January 18, 2022 Resubmission of the 505(b)(2) New Drug Application for M207

Zosano Pharma Corporation has completed a Composite Units Offering in the amount of $15.375 million.

Zosano Pharma Corporation has completed a Composite Units Offering.

Zosano Pharma Corporation Resubmits its M207 (Zolmitriptan Transdermal Microneedle System) 505(B)(2) New Drug Application to the U.S. Food and Drug Administration

Zosano Pharma Announces Publication of Clinical Data Demonstrating Comparable Immunogenicity of A Trivalent Influenza Vaccine Formulated on Its Transdermal Microneedle System Versus an Intramuscular Injection of the Vaccine At A Higher Dose

Zosano Pharma Corporation Announces Publication of Clinical Data Regarding the Long-Term Use of Qtrypta for the Treatment of Acute Migraine in the Journal of Headache and Pain

Zosano Pharma Confirms Plan to Move Forward with Pharmacokinetic Study Following Protocol Review by FDA

Revenue in line with expectations

Zosano Pharma Corporation Announces John Walker, Chairman of the Board of Directors to Retire from the Board

Zosano Pharma Confirms NDA Resubmission Strategy Following Type A Meeting Minutes from FDA

New 90-day high: €1.26

Zosano Pharma Corporation Announces NDA Resubmission Plans Following Type A Meeting with FDA

New 90-day high: €0.90

New 90-day high: €0.64

Zosano Pharma Requests Type A Meeting with the Fda to Review Resubmission Plans for Qtrypta™ New Drug Application

Bragar Eagel & Squire, P.C. Reminds Investors of Class Action Lawsuit Filed Against Zosano Pharma Corporation

Pomerantz LLP Reminds Shareholders with Losses on Their Investment in Zosano Pharma Corporation of Class Action Lawsuit and Upcoming Deadline

New 90-day low: €0.21

Rosen Announces Filing of Securities Class Action Lawsuit Against Zosano Pharma Corporation

New 90-day low: €0.54

New 90-day low: €0.64

Zosano Pharma Corporation Receives Discipline Review Letter from the U.S. Food and Drug Administration in Connection with the Qtrypta

Zosano Pharma Corporation has completed a Follow-on Equity Offering in the amount of $20.782018 million.

New 90-day high - €1.11

Zosano Pharma Corporation(NasdaqCM:ZSAN) dropped from Russell Microcap Growth Index

Rendimenti per gli azionisti

Volatilità dei prezzi

Informazioni sull'azienda

Zosano Pharma Corporation Riepilogo dei fondamenti

0.0x

0.0x

Guadagni e ricavi